# Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients

> **NCT02629965** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 184 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** tiotropium
- **DRUG:** olodaterol
- **DRUG:** tiotropium

## Key facts

- **NCT ID:** NCT02629965
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-12
- **Primary completion:** 2017-03-24
- **Final completion:** 2017-04-17
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2019-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02629965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02629965, "Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02629965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*